An interventional study of Pulmonary function Test intervention in Suspected Asthma, sponsored by AstraZeneca. Recruiting at 24 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AstraZeneca · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 72nd largest by planned enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 with no phase, reaches primary completion later than 7 of the 27 other live ones, and was the 353rd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
AstraZeneca · Sites in China
Ages 12–80
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center study to explore the positive predictive value of bronchodilation test with portable oscillometry compared to either BDT or BPT with spirometry in asthma diagnosis and to compare it with bronchodilation with spirometry (the current gold standard). In the study, the target patients' profile is the suspected asthma patient with asthmatic symptoms (wheezing, shortness of breath, chest tightness, and/or cough) and aim to enroll 500 participants from 25 sites across different regions in China.
Following the completion of informed consent procedures, patients with asthmatic symptoms will proceed to enrollment for inclusion and exclusion criteria review. In addition, blood tests, include complete blood count (CBC) and C-reactive protein (CRP), and chest Computed Tomography (CT) will be done for eligible participants prior to all assessments in the study to ensure excluding participants with respiratory infections and any lung diseases (other than asthma).
All the included participants will undergo Fractional exhaled nitric oxide (FeNO) test, BDT with portable oscillometry and spirometry in sequence and complete the Asthma Control Questionnaire-5 (ACQ-5) assessment during Visit 1. For participants with pre-BD FEV1% ≥ 70% will undergo BPT with spirometry as the last assessment in the study.
The diagnosis of asthma will be defined as positive BDT (after bronchodilator inhalation, FEV1 increased by ≥12%, and the absolute value of FEV1 increased by ≥200 mL) or positive BPT with spirometry (FEV1% decrease ≥20% after methacholine inhalation). Oscillometry BDT positive is defined as R5 decrease 40%, or X5 increase 50%, or AX decrease 80% after bronchodilator inhalation as recommended in ERS consensus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all the following criteria and sign an form (ICF) to be eligible for the study.
Exclusion Criteria:
Patients are excluded from the study if any of the following criteria apply:
Medical Conditions
History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months).
Prior/Concomitant Therapy
ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0).
ICS=inhaled ; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists.
Other Exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
enrollment 500 suspect asthma patients
Device: Pulmonary function Test intervention
enrollment 500 suspect asthma patients
To explore the diagnostic value of portable oscillometry in suspected asthma patients
PPV (Positive predictive value)(spiro diagnosed asthma/osci BDT ve+) of BDT(Bronchodilation test) with portable oscillomtery in asthma diagnosis
Time frame: day 0~7
To evaluate the consistency of portable oscillometry BD test with spirometry BDT/BPT in suspected asthma patients
Kappa coefficient between oscillometry BDT and spirometry BDT/BPT and NPV (non-asthma diagnosed by spiro/osci BDT ve-) of BDT with portable oscillometry in asthma diagnosis
Time frame: day 0~7
To evaluate the diagnostic performance of portable oscillometry in suspected asthma patients
Sensitivity (osci BDT ve+/spiro diagnosed asthma) and specificity (osci BDT ve-/non-asthma diagnosed by spiro) of BDT with portable oscillometry in asthma diagnosis. The proportion of osci BDT ve+ who have spiro BPT positive.
Time frame: day 0~7
To evaluate the diagnostic performance of spirometry in suspected asthma patients
Sensitivity (spiro BDT ve+/spiro diagnosed asthma) of BDT with spirometry in asthma diagnosis. The proportion of spiro BDT ve+ who have spiro BPT positive.
Time frame: day 0~7
To evaluate if performing BDT with spirometry and with oscillometry is superior to either test alone
The proportion of osci BDT ve+ who have spiro BDT positive. The proportion of osci BDT ve+ (excluding who have spiro BDT positive) who have spiro BPT positive. The number of asthma patients based on spiro BPT/BDT ve+, who have only osci BDT ve+ or spiro BDT ve+.
Time frame: day 0~7
To evaluate the diagnostic performance of portable oscillometry in asthma patients by lung functions impairment status
PPV and NPV of BDT with portable oscillometry in asthma patients with FEV1%≥70% and FEV1%\<70%, respectively.
Time frame: day 0~7
To explore the diagnostic value of single parameter or combination of parameters in asthma patients
Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) for individual or combination of any parameter of portable oscillometry together with or without FeNO and/or EOS in asthma diagnosis.
Time frame: day 0~7
To explore the diagnostic performance of BDT with portable oscillometry based on thresholds from other studies
The proportion of osci BDT ve+ according to the following thresholds reported in other studies. R5 decrease ≥32% or X5 increase ≥44% or AX decrease ≥65%. R5 decrease ≥29% or X5 increase ≥45%.
Time frame: day 0~7
To describe the change in pulmonary function parameters measured by portable oscillometry before and after bronchodilator use in diagnosed asthma patients
Mean ± SD and percentile ranges (P₂.₅-P₉₇.₅) of the optimal oscillometry BDT variables (e.g., ΔRrs, ΔXrs, ΔAX) in diagnosed asthma patients.
Time frame: day 0~7
To evaluate the safety of portable oscillometry
Adverse events during oscillometry testing.
Time frame: day 0~7
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 12 months is close to that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.